ISONIAZID AND RIFAMPICIN RESISTANCE AND PATIENT TREATMENT RESPONSE IN A TUBERCULOSIS AND HIV-1 CO-ENDEMIC POPULATION IN WESTERN KENYA

被引：0
|
作者：
Likhovole, C. [1 ]
Ouma, C. [1 ]
Khayumbi, J. [2 ]
Murithi, W. [2 ]
Okumu, A. [2 ]
机构：
[1] Maseno Univ, Biomed Sci & Technol, Kisumu, Kenya
[2] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya
来源：
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2019年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
A086
引用
收藏
页码：S277 / S278
页数：2
相关论文
共 50 条
  • [1] ISONIAZID AND RIFAMPICIN RESISTANCE AND PATIENT TREATMENT RESPONSE IN A TUBERCULOSIS AND HIV-1 CO-ENDEMIC POPULATION IN WESTERN KENYA
    Likhovole, Clement
    Ouma, Collins
    Khayumbi, Jeremiah
    Murithi, Wilfred
    Okumu, Albert
    Musau, Susan
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 99 (04): : 184 - 185
  • [2] Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
    Colebunders, R
    Florence, E
    LANCET, 1998, 351 (9118): : 1813 - 1813
  • [3] Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
    Rockwood, Neesha
    Sirgel, Frederick
    Streicher, Elizabeth
    Warren, Robin
    Meintjes, Graeme
    Wilkinson, Robert J.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (06): : 632 - 640
  • [4] Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
    Halsey, NA
    Coberly, JS
    Desormeaux, J
    Losikoff, P
    Atkinson, J
    Moulton, LH
    Contave, M
    Johnson, M
    Davis, H
    Geiter, L
    Johnson, E
    Huebner, R
    Boulos, R
    Chaisson, RE
    LANCET, 1998, 351 (9105): : 786 - 792
  • [5] HIV-1 infection and risk of tuberculosis after rifampicin treatment
    Corbett, EL
    Mallory, KF
    Grant, AD
    Churchyard, GJ
    De Cock, KM
    LANCET, 2001, 357 (9260): : 957 - 958
  • [6] HIV-1 infection and risk of tuberculosis after rifampicin treatment - Reply
    Fitzgerald, DW
    Johnson, WD
    Pape, JW
    LANCET, 2001, 357 (9260): : 958 - 958
  • [7] Prevalence of Non-Tuberculosis Mycobacterium Pulmonary Disease in HIV-1 Patients with Presumptive Pulmonary Tuberculosis in Western Kenya
    Ochayo, Anne
    Wamalwa, Ronald
    Barasa, Erick
    Zablon, Jeremiah
    Sowayi, George
    Were, Tom
    Gitonga, Godfrey
    Shaviya, Nathan
    ETHIOPIAN JOURNAL OF HEALTH SCIENCES, 2023, 33 (05) : 735 - 742
  • [8] Reversible Reduction of Nevirapine Plasma Concentrations During Rifampicin Treatment in Patients Coinfected With HIV-1 and Tuberculosis
    Matteelli, Alberto
    Saleri, Nuccia
    Villani, Paola
    Bonkoungou, Victor
    Carvalho, Anna Cristina C.
    Kouanda, Seni
    Sanou, Marie J.
    Simpore, Jacques
    Monno, Laura
    Carosi, Giampiero
    Regazzi, Mario
    Dembele, Mathurin
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 (01) : 64 - 69
  • [9] A PILOT-STUDY OF ANTITUBERCULOSIS COMBINATIONS COMPARING RIFABUTIN WITH RIFAMPICIN IN THE TREATMENT OF HIV-1 ASSOCIATED TUBERCULOSIS - A SINGLE-BLIND RANDOMIZED EVALUATION IN UGANDAN PATIENTS WITH HIV-1 INFECTION AND PULMONARY TUBERCULOSIS
    SCHWANDER, S
    RUSCHGERDES, S
    MATEEGA, A
    LUTALO, T
    TUGUME, S
    KITYO, C
    RUBARAMIRA, R
    MUGYENYI, P
    OKWERA, A
    MUGERWA, R
    AISU, T
    MOSER, R
    OCHEN, K
    MBONYE, B
    DIETRICH, M
    TUBERCLE AND LUNG DISEASE, 1995, 76 (03): : 210 - 218
  • [10] HIV-1 Molecular Subtypes and Hepatitis Viral Co-infections in a Cohort being Prepared for HIV Clinical Trials, Western Kenya
    Oyaro, M. O.
    Mbithi, J. M.
    Anzala, A. O.
    Engelbrecht, S.
    Oyugi, F.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 160 - 161
12345